|
|
|
|
Protagenic Therapeutics Inc new (PTIX) |
|
Price: $1.8250
$0.04 
1.961%
|
| Day's High:
| $1.825
| Week Perf:
| -0.81 %
|
| Day's Low: |
$ 1.76 |
30 Day Perf: |
-2.24 % |
| Volume (M): |
1 |
52 Wk High: |
$ 2.32 |
| Volume (M$): |
$ 2 |
52 Wk Avg: |
$1.20 |
| Open: |
$1.80 |
52 Wk Low: |
$0.31 |
|
|
| Market Capitalization (Millions $) |
8 |
| Shares
Outstanding (Millions) |
4 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-3 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Protagenic Therapeutics Inc New
Company Address: 149 Fifth Avenue New York 10010 NY
Company Phone Number: 994-8200 Stock Exchange / Ticker: NASDAQ PTIX
| PTIX is expected to report next financial results on November 13, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Benitec Biopharma Inc
Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
|
|
Kintara Therapeutics Inc
Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
|
|
Integrated Biopharma Inc
Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
|
|
Rezolute Inc
Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.
|
|
Cytodyn Inc
Cytodyn Inc., a prominent player in the Major Pharmaceutical Preparations industry, has recently been under scrutiny by industry veterans regarding its performance in the fourth quarter of 2023. The company reported an operating shortfall of $-3.78 million for the period from March to May 2023, without stating any revenue.
One significant aspect that caught the attention of industry observers is the company's ability to operate more cost-effectively compared to the previous year. In the corresponding period of the preceding year, Cytodyn Inc. had an operating shortfall of $-79.048 million. The commendable progress made in reducing these losses could be a positive sign for the company's future prospects, positioning it as a potential bellwether in the industry.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.29 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
1.77 $
|
| Book Value |
1.49 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.29 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
1.77 $
|
| Book Value |
1.49 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights
reserved. This site uses cookies to make your browsing experince better. By
using this site, you agree to the Terms of Service and Privacy Policy - UPDATED
(Read about our Privacy Policy)
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
